In December of 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech and Moderna COVID-19 vaccines in the United States. The District of Columbia Department of Health (DC Health) continues to implement distribution administration recommendations as outlined in the District’s COVID-19 Vaccination Plan. The vaccines have been shown to be safe and effective as determined by the data from the manufacturers and large- scale clinical trials of more than 70,000 individuals drawn from diverse ethnic and socioeconomic backgrounds. Current evidence demonstrates that the known and potential benefits of the vaccine outweigh the known and potential harms associated with COVID-19. This health notice provides information on safe administration, clinical considerations, reporting requirements, and highlights important resources for healthcare providers.
Attachment(s):
mRNA_VACCINE_HAN_Update_DCHealth_COVID-19_2021.3.10_FINAL.pdf
